Intervention
JDQ443
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownJDQ443 for KRAS G12C NSCLC Brain MetastasesNCT05999357 · 2024-04-15
WITHDRAWNNeoadjuvant Platform Trial in Non-Small Cell Lung CancerNCT05714891 · 2023-09-15
ACTIVE_NOT_RECRUITINGStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.NCT05445843 · 2022-12-06
ACTIVE_NOT_RECRUITINGPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24
ACTIVE_NOT_RECRUITINGStudy of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNCT05132075 · 2022-06-15
ACTIVE_NOT_RECRUITINGA Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.NCT05329623 · 2022-05-03
COMPLETEDStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT04699188 · 2021-02-24
ACTIVE_NOT_RECRUITINGCommon conditions
Carcinoma, Non-Small-Cell Lung2KRAS G12C Mutant Solid Tumors2Non-Small Cell Lung Cancer2Brain Metastases, Adult1Cancer of Lung1Cancer of the Lung1Carcinoma, Colorectal1Carcinoma, Non-Small Cell Lung1Colorectal Cancer1Colorectal Carcinoma1Colorectal Neoplasms1Colorectal Tumors1KRAS G12C1Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation1Lung Cancer1Neoplasms, Colorectal1Neoplasms, Lung1Neoplasms, Pulmonary1Non Small Cell Lung Cancer Metastatic1Non-Small Cell Lung Carcinoma1Nonsmall Cell Lung Cancer1NSCLC1Pulmonary Cancer1Pulmonary Neoplasms1Small Cell Lung Carcinoma1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING5
COMPLETED1
WITHDRAWN1
Phase mix
PHASE25
PHASE13
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.